IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+12.69%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$269M
AUM Growth
+$269M
(-5%)
Cap. Flow
+$20.3M
Cap. Flow
% of AUM
7.54%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
130
New
23
Increased
25
Reduced
23
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$15.8M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$13.4M |
| 3 |
Immunovant
IMVT
|
$11.4M |
| 4 |
Akero Therapeutics
AKRO
|
$10.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$9.45M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$12.2M |
| 2 |
Merck
MRK
|
$11.5M |
| 3 |
Biohaven
BHVN
|
$8.36M |
| 4 |
Insmed
INSM
|
$8.34M |
| 5 |
IDEAYA Biosciences
IDYA
|
$7.39M |
Sector Composition
| 1 | Healthcare | 97.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1
DELISTED
ACELYRIN
SLRN
| $29.7M | 3.57% | 2,918,426 | – | – |
|
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $23.6M | 2.84% | 792,920 +317,920 | +67% | +$9.45M |
|
|
3
Soleno Therapeutics
SLNO
$3.6B
| $15.8M | 1.91% | +536,720 | New | +$15.8M |
|
|
4
Rocket Pharmaceuticals
RCKT
$354M
| $13.4M | 1.61% | +654,726 | New | +$13.4M |
|
5
Nuvalent
NUVL
$5.52B
| $12.8M | 1.54% | 278,034 +5,282 | +2% | +$243K |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $12.5M | 1.5% | 473,126 +43,440 | +10% | +$1.15M |
|
|
7
Immunovant
IMVT
$2.56B
| $11.4M | 1.38% | +297,794 | New | +$11.4M |
|
|
8
Akero Therapeutics
AKRO
$3.74B
| $10.1M | 1.22% | +200,000 | New | +$10.1M |
|
9
Tarsus Pharmaceuticals
TARS
$2.47B
| $9.21M | 1.11% | +518,519 | New | +$9.21M |
|
10
Vaxcyte
PCVX
$4B
| $7.26M | 0.87% | 142,417 +2,417 | +2% | +$123K |
|
11
Structure Therapeutics
GPCR
$1.11B
| $6.95M | 0.84% | +137,824 | New | +$6.95M |
|
12
Disc Medicine
IRON
$2.07B
| $6.71M | 0.81% | 142,766 -97,265 | -41% | -$4.57M |
|
13
Ultragenyx Pharmaceutical
RARE
$2.89B
| $6.24M | 0.75% | 174,945 +53,287 | +44% | +$1.9M |
|
|
IMGN
14
DELISTED
Immunogen Inc
IMGN
| $6.19M | 0.74% | 390,162 -57,538 | -13% | -$913K |
|
|
MRNS
15
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.01M | 0.72% | 746,069 +134,137 | +22% | +$1.08M |
|
16
Catalyst Pharmaceutical
CPRX
$2.52B
| $5.91M | 0.71% | +505,862 | New | +$5.91M |
|
|
17
IDEAYA Biosciences
IDYA
$2.15B
| $5.85M | 0.7% | 216,949 -273,944 | -56% | -$7.39M |
|
18
Lyra Therapeutics
LYRA
$11.5M
| $4.9M | 0.59% | 1,254,384 +275,758 | +28% | +$1.08M |
|
19
Arcus Biosciences
RCUS
$1.13B
| $4.58M | 0.55% | 254,876 -25,124 | -9% | -$451K |
|
|
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
| $4.12M | 0.5% | +178,360 | New | +$4.12M |
|
|
21
Insmed
INSM
$28.8B
| $3.91M | 0.47% | 154,900 -330,100 | -68% | -$8.34M |
|
22
Praxis Precision Medicines
PRAX
$958M
| $3.85M | 0.46% | +2,250,000 | New | +$3.85M |
|
23
iTeos Therapeutics
ITOS
$449M
| $3.79M | 0.46% | +346,471 | New | +$3.79M |
|
24
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $3.24M | 0.39% | +865,787 | New | +$3.24M |
|
|
LBPH
25
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $2.86M | 0.34% | 514,101 +9,848 | +2% | +$54.8K |
|